628 related articles for article (PubMed ID: 30874850)
1. Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
Jullien M; Trudel S; Tessoulin B; Mahé B; Dubruille V; Blin N; Gastinne T; Bonnet A; Lok A; Lebourgeois A; Peterlin P; Garnier A; Chevalier P; Guillaume T; Thomaré P; Le Gouill S; Moreau P; Touzeau C
Ann Hematol; 2019 Jun; 98(6):1435-1440. PubMed ID: 30874850
[TBL] [Abstract][Full Text] [Related]
2. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Vozella F; Siniscalchi A; Rizzo M; Za T; Antolino G; Coppetelli U; Piciocchi A; Andriani A; Annibali O; De Rosa L; Cimino G; La Verde G; De Stefano V; Cantonetti M; di Toritto TC; Petrucci MT
Ann Hematol; 2021 Apr; 100(4):1059-1063. PubMed ID: 33528611
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma.
Salomon-Perzyński A; Walter-Croneck A; Usnarska-Zubkiewicz L; Dytfeld D; Zielińska P; Wojciechowska M; Hołojda J; Robak P; Pasternak A; Knopińska-Posłuszny W; Hawrylecka D; Wójtowicz M; Szeremet A; Osowiecki M; Mordak-Domagała M; Zaucha JM; Giannopoulos K; Warzocha K; Jamroziak K
Adv Med Sci; 2019 Sep; 64(2):349-355. PubMed ID: 31125864
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.
Oostvogels R; Jak M; Raymakers R; Mous R; Minnema MC
Br J Haematol; 2018 Oct; 183(1):60-67. PubMed ID: 30080247
[TBL] [Abstract][Full Text] [Related]
5. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
[TBL] [Abstract][Full Text] [Related]
6. Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.
Chehab S; Panjic EH; Gleason C; Lonial S; Nooka AK
Future Oncol; 2018 Dec; 14(30):3111-3121. PubMed ID: 30136602
[TBL] [Abstract][Full Text] [Related]
7. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Lonial S; Weiss BM; Usmani SZ; Singhal S; Chari A; Bahlis NJ; Belch A; Krishnan A; Vescio RA; Mateos MV; Mazumder A; Orlowski RZ; Sutherland HJ; Bladé J; Scott EC; Oriol A; Berdeja J; Gharibo M; Stevens DA; LeBlanc R; Sebag M; Callander N; Jakubowiak A; White D; de la Rubia J; Richardson PG; Lisby S; Feng H; Uhlar CM; Khan I; Ahmadi T; Voorhees PM
Lancet; 2016 Apr; 387(10027):1551-1560. PubMed ID: 26778538
[TBL] [Abstract][Full Text] [Related]
8. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F
Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience.
Byun JM; Yoon SS; Koh Y; Kim I; Jo J; Park H; Lee JO; Lee J
Anticancer Res; 2019 Sep; 39(9):5165-5170. PubMed ID: 31519629
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
[No Abstract] [Full Text] [Related]
11. Daratumumab in multiple myeloma.
Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
[TBL] [Abstract][Full Text] [Related]
12. Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma.
Steinhardt MJ; Zhou X; Krummenast F; Meckel K; Nickel K; Böckle D; Messerschmidt J; Knorz S; Dierks A; Heidemeier A; Lapa C; Einsele H; Rasche L; Kortüm KM
Int J Immunopathol Pharmacol; 2020; 34():2058738420980258. PubMed ID: 33353443
[TBL] [Abstract][Full Text] [Related]
13. Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis.
Pick M; Vainstein V; Goldschmidt N; Lavie D; Libster D; Gural A; Grisariu S; Avni B; Ben Yehuda D; Gatt ME
Eur J Haematol; 2018 May; 100(5):494-501. PubMed ID: 29453884
[TBL] [Abstract][Full Text] [Related]
14. Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population.
Minarik J; Pour L; Maisnar V; Spicka I; Jungova A; Jelinek T; Brozova L; Krhovska P; Scudla V; Hajek R
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2019 Sep; 163(3):279-283. PubMed ID: 30397362
[TBL] [Abstract][Full Text] [Related]
15. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
Chari A; Lonial S; Mark TM; Krishnan AY; Stockerl-Goldstein KE; Usmani SZ; Londhe A; Etheredge D; Fleming S; Liu B; Ukropec J; Lin TS; Jagannath S; Nooka AK
Cancer; 2018 Nov; 124(22):4342-4349. PubMed ID: 30395359
[TBL] [Abstract][Full Text] [Related]
16. 3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.
Chim CS; Kumar S; Wong VKC; Ngai C; Kwong YL
Hematology; 2021 Dec; 26(1):652-655. PubMed ID: 34474661
[TBL] [Abstract][Full Text] [Related]
17. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.
Usmani SZ; Diels J; Ito T; Mehra M; Khan I; Lam A
Am J Hematol; 2017 Aug; 92(8):E146-E152. PubMed ID: 28474745
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
Usmani SZ; Nahi H; Plesner T; Weiss BM; Bahlis NJ; Belch A; Voorhees PM; Laubach JP; van de Donk NWCJ; Ahmadi T; Uhlar CM; Wang J; Feng H; Qi M; Richardson PG; Lonial S
Lancet Haematol; 2020 Jun; 7(6):e447-e455. PubMed ID: 32470437
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials.
Lakshman A; Abeykoon JP; Kumar SK; Rajkumar SV; Dingli D; Buadi FK; Gonsalves WI; Leung N; Dispenzieri A; Kourelis TV; Go RS; Lacy MQ; Hobbs MA; Lin Y; Warsame R; Lust J; Fonder AL; Hwa YL; Hayman SR; Russell SJ; Kyle RA; Gertz MA; Kapoor P
Am J Hematol; 2017 Nov; 92(11):1146-1155. PubMed ID: 28799231
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey.
Markovic U; Romano A; Del Fabro V; Bellofiore C; Bulla A; Parisi MS; Leotta S; Gentile M; Cangialosi C; Vincelli I; Mineo G; Rossi M; Poidomani M; Uccello G; Maugeri C; Mannina D; Innao V; Di Raimondo F; Conticello C
Front Oncol; 2021; 11():624405. PubMed ID: 33763359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
